Alambic Investment Management L.P. raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 100.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,998 shares of the biopharmaceutical company’s stock after buying an additional 7,518 shares during the period. Alambic Investment Management L.P.’s holdings in Celgene Corporation were worth $1,866,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Motco increased its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter worth about $118,000. Carroll Financial Associates Inc. increased its position in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. increased its position in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Finally, Reilly Financial Advisors LLC increased its position in shares of Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares during the period. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) opened at 136.70 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company’s 50 day moving average price is $132.00 and its 200-day moving average price is $123.32. The stock has a market capitalization of $106.95 billion, a PE ratio of 42.34 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.44 earnings per share. Analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Position Raised by Alambic Investment Management L.P.” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/05/celgene-corporation-celg-position-raised-by-alambic-investment-management-l-p.html.

A number of brokerages have issued reports on CELG. Cantor Fitzgerald set a $159.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, April 27th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a research note on Monday, July 31st. BMO Capital Markets restated an “outperform” rating and issued a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Tuesday, June 6th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and an average price target of $147.06.

In other news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,255 shares of company stock valued at $31,377,042. Corporate insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.